EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Risk assessment for hypocalcemia in therapeutic apheresis for kidney transplantation

Chimezie Godswill Okwuonu iD, Monarch Shah iD, Iram Rafique iD, Abdallah Saleh Abdelrazeq iD, Korshie Dumor, Rasheed A Balogun iD

Therapeutic Apheresis and Dialysis · 2024

DOI: 10.1111/1744-9987.14168 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Apheresis and Dialysis, 2024. Verfasst von Chimezie Godswill Okwuonu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, University of Virginia Health, Charlottesville, Virginia, USA. Hauptthemen laut MEDLINE: Hypocalcemia, Kidney Transplantation, Blood Component Removal. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: International Society of Nephrology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The increase in the number of kidney transplants performed in the United States has been paralleled with an increase in the utilization of therapeutic apheresis (TA) for kidney transplant indications. Hypocalcemia remains a significant contributor to the adverse event in TA. The magnitude of hypocalcemia and its risk factors are scarcely discussed in literature.

Methods

This is a retrospective cohort review of adults from 18 years and above who received TA for kidney transplant‐related indications from January 1, 2017 to December 31, 2022. Data extracted included basic demographics, indication for apheresis, procedure characteristics, serum ionized calcium at the mid and end of procedure and serum creatinine at the beginning of apheresis, and so forth.

Results

Data from 131 patients and 860 sessions of TA were analyzed. Antibody‐mediated rejection (69%) and recurrent FSGS (15%) were the leading indications for TA. There were 60 (7%) TA sessions complicated by hypocalcemia. Of these, 53 (88%) occurred in the first session, 5 (8%) occurred in second session while 2 (4%) occurred in the third and subsequent sessions. Female sex, elevated serum creatinine and use of fresh frozen plasma‐ are the risk factors for hypocalcemia with odd's ratio of 2.34, 7.42, and 5.01, respectively. Binary logistic regression showed that elevated serum creatinine at the commencement of therapy is an independent predictor of hypocalcemia (adjusted odd's ratio = 3.31, p = 0.001).

Conclusion

Hypocalcemia is prevalent in this study. Clinical vigilance and tailored procedure will avert adverse consequences.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypocalcemiaKidney TransplantationBlood Component RemovalHumansFemaleMaleRetrospective StudiesAdultMiddle AgedRisk AssessmentRisk FactorsGraft RejectionCreatinine

Stichwörter der Autor:innen

hypocalcemiakidney transplantationtherapeutic apheresis

Substanzen

Creatinine

Autor:innen und Institutionen

  • Division of Nephrology, University of Virginia Health, Charlottesville, Virginia, USA.
  • Federal Medical Centre Umuahia, Abia, Nigeria.

ORCID-Profile: Chimezie Godswill Okwuonu, Monarch Shah, Iram Rafique, Abdallah Saleh Abdelrazeq, Rasheed A Balogun

Förderung

  • International Society of Nephrology

Zitieren

APA

Okwuonu, C. G., Shah, M., Rafique, I., Abdelrazeq, A. S., Dumor, K., & Balogun, R. A. (2024). Risk assessment for hypocalcemia in therapeutic apheresis for kidney transplantation. Therapeutic Apheresis and Dialysis. https://doi.org/10.1111/1744-9987.14168

Vancouver

Okwuonu CG, Shah M, Rafique I, Abdelrazeq AS, Dumor K, Balogun RA. Risk assessment for hypocalcemia in therapeutic apheresis for kidney transplantation. Therapeutic Apheresis and Dialysis. 2024. doi:10.1111/1744-9987.14168

BibTeX
@article{Okwuonu2024,
  author = {Okwuonu, Chimezie Godswill and Shah, Monarch and Rafique, Iram and Abdelrazeq, Abdallah Saleh and Dumor, Korshie and Balogun, Rasheed A},
  title = {Risk assessment for hypocalcemia in therapeutic apheresis for kidney transplantation},
  journal = {Therapeutic Apheresis and Dialysis},
  year = {2024},
  doi = {10.1111/1744-9987.14168}
}
Kostenlos starten →